Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Log Plug-and-play starting point Data Integrity

Log: Data Integrity Leading Indicators Tracking Log

A plug-and-play trending log for the leading indicators that surface data integrity culture and control problems before they become inspection findings: OOS invalidation rate, batch record amendment rate, after-hours access frequency, and CDS re-injection rate, with review triggers and a filled specimen.

Document type: Log

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use tracking log. Replace every <<FILL: ...>> placeholder with your own specifics and feed it into your standing quality metrics review. A worked filled specimen follows the template. The indicators here are starting points for discussion, not regulatory limits; the point is the trend, not any single period’s number.

Purpose

These four indicators, trended over time, surface data integrity culture and control problems before they surface as 483 observations or warning letter citations. A single period tells you little. The same number drifting in one direction across a year tells you something is changing in how work is actually done. This log makes that trend visible and reviewable.

Indicator definitions

IndicatorNumeratorDenominatorWhat it signals
OOS invalidation rateCount of OOS results closed as assignable laboratory errorTotal OOS results in the periodPressure to find a lab-error justification rather than accept a genuine result
Batch record amendment rateCount of batch record amendments made after the recording shift/stepTotal batch records in the periodRecords not captured contemporaneously; late corrections clustered before release deserve scrutiny
After-hours access frequencyCount of unexplained system access events outside scheduled hoursTotal access events in the periodWork happening outside oversight; investigate unexplained spikes, not the baseline
CDS re-injection rateCount of re-injectionsTotal injections in the periodTesting into compliance; watch the trend, not the absolute number

Tracking log

PeriodSystem(s)OOS invalidation rateBatch amendment rateAfter-hours access (unexplained)CDS re-injection rateReviewerReview dateEscalated?
<<FILL: e.g. Q1 2026>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>>

Review trigger

Escalate to a data integrity self-audit or a targeted investigation per <<FILL: SOP-ID>> when any indicator shows a sustained directional trend across three or more consecutive periods, not on a single period’s value. A single high-OOS-invalidation quarter driven by one known root cause (for example a documented instrument fault, resolved) is not automatically an escalation; the same pattern repeating after the fix is.

Instructions

  1. Calculate each indicator at a consistent cadence, <<FILL: e.g. quarterly>>, from the same source systems each period so the trend is comparable.
  2. Record the reviewer and review date even when no escalation is warranted; a log with gaps is itself a finding.
  3. Where a period’s number is elevated, record the known cause if one exists (instrument fault, staffing change, a specific investigation) so future reviewers can distinguish an explained blip from a genuine drift.
  4. Feed this log into the standing quality metrics and KPIs program so indicators are reviewed on a fixed cadence rather than only when someone remembers to look.

Retention

Retain this log for <<FILL: retention period>>, consistent with the retention period for the underlying quality records the indicators are drawn from.

References

FDA Data Integrity and Compliance With Drug CGMP guidance (December 2018). MHRA GxP Data Integrity Guidance and Definitions (March 2018).


Filled specimen

PeriodSystem(s)OOS invalidation rateBatch amendment rateAfter-hours access (unexplained)CDS re-injection rateReviewerReview dateEscalated?
Q1 2026QC Analytical, CDS-HPLC-0718% (4 of 22 OOS)6%2 events3.1%R. Gomez2026-04-10No
Q2 2026QC Analytical, CDS-HPLC-0731% (7 of 23 OOS)7%5 events5.8%R. Gomez2026-07-08Yes, DI self-audit triggered
Q3 2026QC Analytical, CDS-HPLC-07<<FILL>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>><<FILL>>

The Q2 review shows the pattern this log exists to catch: OOS invalidation rate and re-injection rate both moved in the same direction in the same quarter, which is a stronger signal together than either number alone, and it was the trigger for the self-audit documented in the DI self-audit summary report for that period.

Common inspection findings this log prevents

  • Leading indicators mentioned in a quality manual as a concept but never actually tracked as numbers over time.
  • A rising re-injection or OOS invalidation rate that was visible in the raw data for a year before anyone connected it to a data integrity risk.
  • Metrics reviewed once and then abandoned, with no reviewer or review date evidencing an ongoing cadence.

How to adapt this log

  1. Add indicators specific to your operation (for example an EBR correction rate for manufacturing-heavy sites) using the same numerator/denominator/signal structure.
  2. Set the review cadence and escalation threshold to match the criticality and volume of the systems tracked.
  3. Link an escalation directly to the DI self-audit checklist and its summary report template so a trend finding routes into the same structured process as any other self-audit finding.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.